NCT05030025 - Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

August 29, 2021

Study Completion Date

August 29, 2021

Conditions

HIV-1-infection

Interventions

COMBINATION_PRODUCT

abacavir, dolutegravir and lamivudine dispersible tablets

Abacavir, Dolutegravir and Lamivudine Dispersible Tablets, 60 mg/5 mg/30 mg Dose: 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg)

COMBINATION_PRODUCT

Triumeq Dispersible Tablets 5 mg GSK1349572 [Dolutegravir]/ 60 mg Abacavir/ 30 mg Lamivudine

Triumeq Dispersible Tablets 5 mg GSK1349572 \[Dolutegravir\]/ 60 mg Abacavir/ 30 mg Lamivudine Dose: 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg)

Trial Locations (1)

Altasciences, Montreal